MBI files for approval of FS069

Molecular Biosystems of San Diego has filed a premarket approvalapplication for FS069, its second-generation ultrasound contrastagent. The submission involved clinical studies for cardiac function,focusing on enhancing endocardial border delineation. In addition,MBI hopes to get approval to use the agent for opacification ofthe left ventricular chamber. MBI has granted Mallinckrodt Medicallicenses to market FS069 in the U.S. and in a number of internationalmarkets (SCAN 12/18/96).